Transaction overview
Currier Plastics, a U.S.-based contract manufacturer specializing in custom plastic components for life sciences customers, completed the acquisition of Springboard Manufacturing on January 8, 2025. The transaction's financial details were not disclosed but involved a 100% equity stake in Springboard. Currier Plastics is a portfolio company of Sheridan Capital Partners, a private equity firm focused on healthcare businesses.
Deal structure and financing
The acquisition of Springboard was financed through a mix of debt and equity capital, with Fidelity providing the necessary debt funding for the deal. While specific figures were not disclosed, the transaction did involve a material stake being retained by HC Private Investments, the previous owner of Springboard Manufacturing. Additionally, it is noteworthy that John Weber, former CEO of Springboard, has joined Currier's Board of Directors as part of the acquisition agreement. No lock-up terms or IPO options for Springboard were mentioned in the transaction details.
Strategic context
Currier Plastics aims to expand its service offerings and enhance its life sciences capabilities through this acquisition. The addition of Springboard Manufacturing will enable Currier to significantly increase its cleanroom capacity, particularly on the West Coast. This strategic move aligns with Currier's goal to serve a broader array of life sciences customers while realizing substantial economies of scale. Furthermore, Springboard’s expertise in custom-molded precision components and tooling complements Currier’s existing capabilities, creating a more comprehensive service portfolio for its clients.
Regulatory path
To date, no specific regulatory scrutiny or filings have been disclosed regarding the acquisition of Springboard Manufacturing by Currier Plastics. Given that both companies operate within the United States and provide services primarily to life sciences customers, it is likely that they will need to comply with U.S. antitrust regulations, potentially involving a review by the Federal Trade Commission (FTC) or the Antitrust Division of the Department of Justice (DOJ). However, due to the undisclosed nature of the transaction's financial details and specific regulatory filings, no concrete information on the regulatory path is available as of January 2025.